Were Analysts Bearish ArQule, Inc. (NASDAQ:ARQL) This Week?

April 22, 2018 - By Dolores Ford

ArQule, Inc. (NASDAQ:ARQL) Logo

ArQule, Inc. (NASDAQ:ARQL) Ratings Coverage

Among 5 analysts covering Arqule (NASDAQ:ARQL), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arqule had 5 analyst reports since December 14, 2017 according to SRatingsIntel. The company was initiated on Friday, February 2 by FBR Capital. The firm has “Buy” rating by B. Riley & Co given on Monday, February 12. The stock has “Buy” rating by Needham on Thursday, December 14. Leerink Swann upgraded it to “Buy” rating and $500 target in Thursday, April 5 report. Below is a list of ArQule, Inc. (NASDAQ:ARQL) latest ratings and price target changes.

05/04/2018 Broker: Leerink Swann Rating: Buy New Target: $5.0000 Upgrade
22/02/2018 Broker: Roth Capital Rating: Buy New Target: $5 Initiates Coverage On
12/02/2018 Broker: B. Riley & Co Rating: Buy Old Target: $3 New Target: $3.5 Maintain
02/02/2018 Broker: FBR Capital Rating: Buy New Target: $3.0 Initiate
14/12/2017 Broker: Needham Old Rating: Hold New Rating: Buy Upgrade

The stock decreased 2.71% or $0.08 during the last trading session, reaching $2.87. About 1.01 million shares traded or 22.05% up from the average. ArQule, Inc. (NASDAQ:ARQL) has risen 180.00% since April 22, 2017 and is uptrending. It has outperformed by 168.45% the S&P500.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company has market cap of $250.01 million. The Company’s lead product candidate is tivantinib , a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. It currently has negative earnings. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death.

ArQule, Inc. (NASDAQ:ARQL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: